News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,084 Results
Type
Article (14923)
Company Profile (299)
Press Release (266856)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79843)
Career Advice (163)
Deals (13338)
Drug Delivery (39)
Drug Development (50708)
Employer Resources (31)
FDA (5843)
Job Trends (5170)
News (145101)
Policy (10073)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (21)
Adcomms (14)
Allergies (85)
Alliances (21761)
ALS (127)
Alzheimer's disease (1040)
Antibody-drug conjugate (ADC) (248)
Approvals (6042)
Artificial intelligence (269)
Autoimmune disease (124)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (103)
Biotechnology (230)
Bladder cancer (102)
Brain cancer (47)
Breast cancer (349)
Cancer (3188)
Cardiovascular disease (241)
Career advice (148)
Career pathing (8)
CAR-T (225)
CDC (5)
Cell therapy (580)
Cervical cancer (14)
Clinical research (43751)
Collaboration (1176)
Company closure (2)
Compensation (610)
Complete response letters (43)
COVID-19 (1102)
CRISPR (91)
C-suite (577)
Cystic fibrosis (112)
Data (4393)
Denatured (15)
Depression (96)
Diabetes (257)
Diagnostics (1385)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (198)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (220)
Earnings (31709)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51761)
Executive appointments (631)
FDA (7622)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (997)
Gene editing (188)
Generative AI (22)
Gene therapy (498)
GLP-1 (508)
Government (1151)
Grass and pollen (3)
Guidances (166)
Healthcare (6615)
HIV (19)
Huntington's disease (44)
IgA nephropathy (75)
Immunology and inflammation (197)
Immuno-oncology (44)
Indications (75)
Infectious disease (1214)
Inflammatory bowel disease (160)
Inflation Reduction Act (10)
Influenza (42)
Intellectual property (171)
Interviews (18)
IPO (7347)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (24)
Layoffs (244)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (429)
Lymphoma (254)
Machine learning (24)
Management (7)
Manufacturing (382)
MASH (133)
Medical device (2667)
Medtech (2676)
Mergers & acquisitions (6626)
Metabolic disorders (737)
Multiple sclerosis (107)
NASH (13)
Neurodegenerative disease (238)
Neuropsychiatric disorders (70)
Neuroscience (1982)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (336)
Opinion (126)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (167)
Parkinson's disease (234)
Partnered (12)
Patents (313)
Patient recruitment (349)
Peanut (44)
People (26710)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15502)
Phase 2 (20330)
Phase 3 (12837)
Pipeline (3437)
Policy (92)
Postmarket research (853)
Preclinical (6546)
Press Release (30)
Prostate cancer (148)
Psychedelics (50)
Radiopharmaceuticals (242)
Rare diseases (666)
Real estate (1448)
Recruiting (12)
Regulatory (9953)
Reports (20)
Research institute (975)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (186)
Series B (140)
Service/supplier (1)
Sickle cell disease (79)
Special edition (19)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (345)
Venture capital (70)
Weight loss (174)
Women's health (27)
Worklife (2)
Date
Today (87)
Last 7 days (303)
Last 30 days (1272)
Last 365 days (17823)
2026 (2172)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18283)
Australia (3117)
California (7185)
Canada (1873)
China (786)
Colorado (250)
Connecticut (258)
Delaware (239)
Europe (39248)
Florida (920)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (400)
India (36)
Indiana (164)
Iowa (8)
Japan (231)
Kansas (81)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (745)
Massachusetts (5660)
Michigan (110)
Minnesota (252)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1669)
New Mexico (13)
New York (1787)
North Carolina (844)
North Dakota (6)
Northern California (3540)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1296)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2851)
Tennessee (41)
Texas (927)
United States (23686)
Utah (98)
Virginia (140)
Washington D.C. (37)
Washington State (595)
West Virginia (1)
Wisconsin (47)
282,084 Results for "volastra therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strategy
January 7, 2026
·
5 min read
Press Releases
Volastra Therapeutics Announces Appointment of David P. Southwell as Chief Executive Officer
May 27, 2025
·
2 min read
Drug Development
Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib
Volastra Therapeutics today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).
April 16, 2024
·
3 min read
Business
Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics
Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, announced an innovative research and development partnership with Volastra Therapeutics, a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability.
March 26, 2024
·
2 min read
Business
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.
November 6, 2023
·
2 min read
Press Releases
Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting
May 23, 2025
·
4 min read
Press Releases
Volastra Therapeutics Announces the Appointment of Co-Founder Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer
October 16, 2024
·
3 min read
Press Releases
Volastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in Ovarian Cancer
October 2, 2024
·
2 min read
Drug Development
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
Volastra Therapeutics , a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.
October 30, 2023
·
2 min read
Drug Development
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
Volastra Therapeutics released preclinical data from the company’s portfolio of KIF18A inhibitors at the 2023 American Association for Cancer Research Annual Meeting in Orlando.
April 16, 2023
·
2 min read
1 of 28,209
Next
